SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:umu-137406"
 

Search: onr:"swepub:oai:DiVA.org:umu-137406" > A model using conco...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

A model using concomitant markers for predicting outcome in human papillomavirus positive oropharyngeal cancer

Bersani, Cinzia (author)
Karolinska Institutet
Mints, Michael (author)
Karolinska Institutet,Umeå universitet,Institutionen för kirurgisk och perioperativ vetenskap,Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden
Tertipis, Nikolaos (author)
show more...
Haeggblom, Linnea (author)
Karolinska Institutet
Sivars, Lars (author)
Karolinska Institutet
Ährlund-Richter, Andreas (author)
Vlastos, Andrea (author)
Smedberg, Cecilia (author)
Grün, Nathalie (author)
Munck-Wikland, Eva (author)
Karolinska Institutet
Näsman, Anders (author)
Karolinska Institutet
Ramqvist, Torbjörn (author)
Karolinska Institutet
Dalianis, Tina (author)
Karolinska Institutet
show less...
 (creator_code:org_t)
Elsevier, 2017
2017
English.
In: Oral Oncology. - : Elsevier. - 1368-8375 .- 1879-0593. ; 68, s. 53-59
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Objective: Head-neck cancer therapy has become intensified. With radiotherapy alone, 3-year disease-free survival (DFS) is 80% for HPV-positive TSCC/BOTSCC and better for patients with favorable characteristics, suggesting therapy could be tapered for some, decreasing side-effects. Therefore, we built a model to predict progression-free survival for patients with HPV-positive TSCC and BOTSCC. Material and methods: TSCC/BOTSCC patients treated curatively between 2000 and 2011, with HPV16 DNA/E7 mRNA positive tumors examined for CD8(+) TILs, HPV16 mRNA and HLA class I expression were included. Patients were split randomly 65/35 into training and validation sets, and LASSO regression was used to select a model in the training set, the performance of which was evaluated in the validation set. Results: 258 patients with HPV DNA/E7 mRNA positive tumors could be included, 168 and 90 patients in the respective sets. No treatment improved prognosis compared to radiotherapy alone. CD8(+) TIL counts and young age were the strongest predictors of survival, followed by T-stage <3 and presence of HPV16 E2 mRNA. The model had an area under curve (AUC) of 76%. A model where the presence of three of four of these markers defined good prognosis captured 56% of non-relapsing patients with a positive predictive value of 98% in the validation set. Furthermore, the model identified 35% of our cohort that was over-treated and could safely have received de-escalated therapy. Conclusion: CD8(+) TIL counts, age, T-stage and E2 expression could predict progression-free survival, identifying patients eligible for randomized trials with milder treatment, potentially reducing side effects without worsening prognosis.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Odontologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Dentistry (hsv//eng)

Keyword

HPV
Oropharyngeal cancer tonsillar cancer
Base of tongue cancer
Biomarkers
Survival

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view